All Sections

Site Selection

Facility Planning

Workforce Development

Business+Place

AD Editorial Board

Alan Reeves

Senior Managing Director, Global Strategy, Newmark
Alexandra Segers

General Manager, Tochi Advisors
Amy Gerber

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Bradley Migdal

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Brian Corde

Managing Partner, Atlas Insight
Brian Gallagher

Vice President, Corporate Strategy and Development, PPC Partners, Inc.
Chris Chmura, Ph.D.

CEO & Founder, Chmura Economics
Chris Schwinden

Partner, Site Selection Group
Chris Volney

Managing Director, Americas Consulting, CBRE
Courtland Robinson

Director of Business Development, Brasfield & Gorrie
Courtney Dunbar

Site Selection & Economic Development Leader, Burns & McDonnell
David Hickey

Managing Director, Hickey & Associates
Dennis Cuneo

Former Senior Vice President, Toyota Motor North America; Owner , DC Strategic Advisors
Dianne Jones

Managing Director, Business and Economic Incentives, JLL
Eric Stavriotis

Vice Chairman, CBRE
Joe Dunlap

Chief Supply Chain Officer, Legacy Investing
Lauren Berry

Senior Manager, Location Analysis and Incentives, Maxis Advisors
Marc Beauchamp

President, SCI Global
Matthew Powers

Site Selection Lead, REDI Site Selection
Scott J. Ziance

Partner and Economic Incentives Practice Leader, Vorys, Sater, Seymour and Pease LLP
Scott Kupperman

Founder, Kupperman Location Solutions
Stephen Gray

President & CEO, Gray Construction

Apozeal Pharmaceuticals Expands Bucks County, Pennsylvania, Drug Manufacturing Operations

Area Development News Desk

09/14/2025

Pharmaceutical company Apozeal Pharmaceuticals Inc. plans to expand its operations in Levittown, Pennsylvania. The $4.1 million project is expected to create 70 jobs in Bucks County.

The investment will include new production lines at the company’s existing 70,000-square-foot facility, enabling it to manufacture the remaining seven ANDA products and additional OTC products.

“We’d like to thank Governor Shapiro and his team for their support and investment of $1.1 million towards this expansion,” said Sadath Shareef, Chairman and CEO of Apozeal. “Their support was instrumental in helping bring this project to life. Through this expansion, we are bringing 70 new jobs to the region, and will have the opportunity to greatly expand our product line.”

To support the project Apozeal Pharmaceuticals received a funding proposal from the Pennsylvania Department of Community and Economic Development (DCED) that includes a Pennsylvania Industrial Development Authority (PIDA) loan of $925,000, a $150,000 Pennsylvania First Grant, and a $100,000 WEDnet grant to train its workers.

“Life sciences is one of the five key sectors outlined in our Economic Development Strategy, and we’re focused on ensuring this industry continues to thrive in Pennsylvania,” noted DCED Secretary Rick Siger. “Apozeal’s investment is another great example of the growth we’re supporting across the Commonwealth.”

Apozeal Pharmaceuticals develops and manufactures high-quality, affordable branded and generic drugs, including oral liquid solutions, suspensions, and suppositories. The company currently owns 11 FDA-approved Abbreviated New Drug Application products along with several over-the-counter items for cough, cold, pain, and fever.

Project Announcements